{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:47:32Z","timestamp":1786988852085,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100407","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T23:22:28Z","timestamp":1646263348000},"page":"100407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Y.","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100407_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/1097-0142(19950101)75:1+<353::AID-CNCR2820751317>3.0.CO;2-P","article-title":"Cancer of unknown primary site","volume":"75","author":"Muir","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100407_bib2","article-title":"Cancer of unknown primary","volume":"371","author":"Lee","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100407_bib3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/bjc.2013.386","article-title":"Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities","volume":"109","author":"Urban","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100407_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canep.2014.03.010","article-title":"Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010","volume":"38","author":"Brewster","year":"2014","journal-title":"Cancer Epidemiol"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100407_bib5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/S0959-8049(02)00135-1","article-title":"Epidemiology of unknown primary tumours","volume":"38","author":"Levi","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100407_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","article-title":"The currently declining incidence of cancer of unknown primary","volume":"61","author":"Rassy","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100407_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3747\/co.25.4003","article-title":"Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario","volume":"25","author":"Kim","year":"2018","journal-title":"Curr Oncol"},{"issue":"9824","key":"10.1016\/j.esmoop.2022.100407_bib8","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100407_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.seminoncol.2008.10.005","article-title":"Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors","volume":"36","author":"Greco","year":"2009","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100407_bib10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","article-title":"Carcinomas of an unknown primary origin\u2014diagnosis and treatment","volume":"8","author":"Massard","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100407_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","article-title":"Molecular characterisation and liquid biomarkers in carcinoma of unknown primary (CUP): taking the \u2018U\u2019 out of \u2018CUP\u2019","volume":"120","author":"Conway","year":"2019","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100407_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41571-020-0359-1","article-title":"Progress in refining the clinical management of cancer of unknown primary in the molecular era","volume":"17","author":"Rassy","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2022.100407_bib13","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100407_bib14","series-title":"Occult primary, version 2.2020","author":"David","year":"2020"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100407_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2010.06.003","article-title":"Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis?","volume":"37","author":"Pentheroudakis","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100407_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1159\/000252797","article-title":"Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years","volume":"32","author":"Th\u00f6m","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.esmoop.2022.100407_bib17","doi-asserted-by":"crossref","first-page":"102882","DOI":"10.1016\/j.critrevonc.2020.102882","article-title":"New rising entities in cancer of unknown primary: is there a real therapeutic benefit?","volume":"147","author":"Rassy","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100407_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00428-014-1545-2","article-title":"Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care","volume":"464","author":"Hainsworth","year":"2014","journal-title":"Virchows Arch"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100407_bib19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neo.2014.09.007","article-title":"RNA-seq accurately identifies cancer biomarker signatures to distinguish tissue of origin","volume":"16","author":"Wei","year":"2014","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100407_bib20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/modpathol.2016.60","article-title":"Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin","volume":"29","author":"Xu","year":"2016","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100407_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijc.31054","article-title":"A\u00a0naive Bayes algorithm for tissue origin diagnosis (TOD-Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system","volume":"142","author":"Jiang","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100407_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12967-019-2082-1","article-title":"90-gene signature assay for tissue origin diagnosis of brain metastases","volume":"17","author":"Zheng","year":"2019","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.esmoop.2022.100407_bib23","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/bib\/bbaa031","article-title":"TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary","volume":"22","author":"Shen","year":"2021","journal-title":"Brief Bioinform"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100407_bib24","doi-asserted-by":"crossref","first-page":"165916","DOI":"10.1016\/j.bbadis.2020.165916","article-title":"A\u00a0machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation","volume":"1866","author":"He","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.esmoop.2022.100407_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fbioe.2020.00701","article-title":"A\u00a0deep learning framework to predict tumor tissue-of-origin based on copy number alteration","volume":"8","author":"Liang","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100407_bib26","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100407_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100407_bib28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100407_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2019.12.016","article-title":"The role of site-specific therapy for cancers of unknown of primary: a meta-analysis","volume":"127","author":"Rassy","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100407_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clon.2018.06.012","article-title":"Site-specific chemotherapy based on predicted primary site by pathological profile for carcinoma of unknown primary site","volume":"30","author":"Hasegawa","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100407_bib31","first-page":"112","article-title":"A\u00a0retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile","volume":"11","author":"Hainsworth","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2022.100407_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"24","key":"10.1016\/j.esmoop.2022.100407_bib33","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statist Med"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100407_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.esmoop.2022.100407_bib35","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"LBA15_PR \u2013 A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2022.100407_bib36","doi-asserted-by":"crossref","first-page":"v228","DOI":"10.1093\/annonc\/mdq193","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Pavlidis","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100407_bib37","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1038\/sj.bjc.6601085","article-title":"Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002)","volume":"89","author":"Bugat","year":"2003","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100407_bib38","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.oraloncology.2012.06.014","article-title":"Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis","volume":"48","author":"Ma","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2022.100407_bib39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ygyno.2021.02.024","article-title":"Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: a meta-analysis","volume":"161","author":"Huang","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100407_bib40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djt099","article-title":"Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology","volume":"105","author":"Greco","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100407_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/path.2915","article-title":"MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin","volume":"225","author":"Ferracin","year":"2011","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.esmoop.2022.100407_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1476-4598-12-57","article-title":"Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary","volume":"12","author":"Pentheroudakis","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2022.100407_bib43","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/1878-0261.13026","article-title":"MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary","volume":"15","author":"Laprovitera","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2022.100407_bib44","doi-asserted-by":"crossref","first-page":"585029","DOI":"10.3389\/fgene.2020.585029","article-title":"A\u00a0novel XGBoost method to identify cancer tissue-of-origin based on copy number variations","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Gene"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100407_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"issue":"6378","key":"10.1016\/j.esmoop.2022.100407_bib46","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"7861","key":"10.1016\/j.esmoop.2022.100407_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","article-title":"AI-based pathology predicts origins for cancers of unknown primary","volume":"594","author":"Lu","year":"2021","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.esmoop.2022.100407_bib48","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100407_bib49","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100407_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100407_bib51","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7378","key":"10.1016\/j.esmoop.2022.100407_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"6382","key":"10.1016\/j.esmoop.2022.100407_bib53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100407_bib54","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","article-title":"Emerging opportunities and challenges in cancer immunotherapy","volume":"22","author":"Whiteside","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100407_bib55","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Gene"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100407_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s40425-019-0720-z","article-title":"Clinical and immune profiling for cancer of unknown primary site","volume":"7","author":"Haratani","year":"2019","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:49Z","timestamp":1761855949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292200028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S205970292200028X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100407","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100407"}}